SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22% SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22%

MVP Medical Developments International Limited

Healthcare · Drug Manufacturers - Specialty & Generic · website
$0.42
52wk 0.36 – 0.77
Overall
65.9
Value
67.7
Growth
93.2
Health
100.0
Quality
16.8
Momentum
30.7
Dividend
—
Price
About Medical Developments International Limited

Medical Developments International Limited provides emergency medical solutions in Australia, Europe, the United States, and internationally. The company operates through Pain Management and Respiratory segments. It manufactures and distributes Penthrox, a fast-acting trauma and emergency pain relief product used in hospital emergency departments, ambulance services, sports medicine, and for analgesia during short surgical procedures. The company also supplies respiratory products, including space chambers, peak flow meters, portable nebulizers, and silicone face masks to aid sufferers of asthma and chronic obstructive pulmonary disease. Medical Developments International Limited was founded in 1972 and is headquartered in Scoresby, Australia.

Price analytics

Returns

1 day -2.3%
1 week -4.5%
1 month -7.6%
3 months 3.7%
6 months 0.0%
1 year -35.1%
3 years -51.4%

Risk

Volatility (1y ann.) 72.3%
Beta vs ASX 200 0.66
Sharpe (1y) -0.32
VaR 95% (1-day) -6.2%
Max drawdown (1y) -51.3%
Off 1-year high -44.1%

Technicals

RSI(14) 11 OS
vs 50DMA -9.8%
vs 200DMA -4.9%
Trend Golden cross
Fundamental trends
Financial statements
Loading…
Scoring breakdown (2 Oct 2026)
Value 67.7
Trailing P/E
0
Forward P/E
88
PEG ratio
—
EV / EBITDA
79
Price / Book
99
Price / Sales
96
Growth 93.2
Revenue growth (1y)
80
Revenue CAGR (3y)
100
EPS growth (1y)
100
EPS CAGR (3y)
—
Financial Health 100.0
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
—
Current ratio
100
Debt / Equity
100
Quality (Profitability & Cash Flow) 16.8
Return on equity
6
Return on assets
23
Operating margin
32
Net margin
10
Cash conversion (OCF / net income)
—
Dividend / Income —
No meaningful dividend — pillar excluded from the overall score.
Momentum 30.7
6-month return vs ASX 200
58
Price vs 200-day average
34
Price vs 50-day average
1
Position in 52-week range
15

Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).

Score history
Key metrics
Market cap
$47.88M
P/E (trailing)
42.50
P/E (forward)
11.18
EPS (trailing)
0.01
Dividend yield
—
Payout ratio
0.0%
Beta
1.41
EV / EBITDA
7.12
Price / Book
0.86
ROE
1.1%
Operating margin
8.1%
Net margin
1.5%
Total cash
$21.37M
Total debt
$1.67M
Current ratio
5.77
Debt / Equity
0.03
Free cash flow
$5.89M
Avg volume
189,173
Latest annual results (FY ending 30 Jun 2026)
  • Revenue—
  • Gross profit—
  • Operating income—
  • Net income—
  • Diluted EPS0.01
  • Free cash flow—
  • Net debt—
Sector peers (Healthcare)
TickerMkt cap P/EScore
CSL $84.15B — 54.3
RMD $45.86B 21.2 74.4
SIG $29.91B 43.3 55.6
FPH $21.64B 57.5 71.1
PME $16.34B 61.8 69.0
RHC $12.56B 40.0 40.2
SHL $9.12B 15.0 43.0
COH $8.20B 55.5 39.4